Quantcast

Latest Putamen Stories

2011-02-03 08:00:00

SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease. This trial was initiated in October 2010 and all 11 centers across the United States are now actively enrolling patients. These sites are among the best movement disorders centers in the country and include Baylor...

2010-11-11 06:00:00

SAN DIEGO, Nov. 11, 2010 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it has closed its Series D preferred financing in the amount of $11.5 million. The current venture round was co-led by Hamilton BioVentures and Alta Partners with participation from MPM Capital and Investor Growth Capital. The funds will be used to help support Ceregene's currently enrolling Phase 2b clinical study of CERE-120 for the treatment of Parkinson's disease. Ceregene also...

2010-10-19 16:49:41

An international collaboration led by academics at the University of Sheffield, has shed new light into Parkinson´s disease, which could help with the development of cures or treatments in the future. The collaboration, which was led by Professor Peter Redgrave from the University´s Department of Psychology, suggests that many of the problems suffered by patients with Parkinson´s disease - difficulties in initiating actions, slow...

2010-10-19 11:26:00

SAN DIEGO, Oct. 19 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment has begun in a new double-blind sham surgery-controlled Phase 2b study evaluating CERE-120 in Parkinson's disease patients. CERE-120 is a gene therapy product that delivers the neurotrophic factor neurturin to degenerating or dying dopamine neurons. Data from the first Phase 2 clinical trial of CERE-120 are being published later this year in Lancet Neurology (to appear online...

2010-06-22 11:30:00

SAN DIEGO, June 22 /PRNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) will provide $2.5 million to support Ceregene Inc.'s new Phase 2 study of CERE-120. This novel gene therapy product delivers the gene for neurturin, a potent neurotrophic (growth) factor that has shown potential to improve the status of degenerating neurons in both preclinical and clinical studies. CERE-120 has the potential to improve motor function as well as slow Parkinson's disease (PD)...

2010-04-28 06:00:00

SAN DIEGO, April 28 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up....

2010-04-19 15:42:36

Integrated functional network could explain some mysteries of Parkinson's and dystonia PITTSBURGH -- Researchers at the University of Pittsburgh have found new evidence that the basal ganglia and the cerebellum, two important areas in the central nervous system, are linked together to form an integrated functional network. The findings are available online this week in the Proceedings of the National Academy of Sciences. "The basal ganglia and the cerebellum are two major subcortical...

2010-01-20 14:46:38

Researchers can predict your performance on a video game simply by measuring the volume of specific structures in your brain, a multi-institutional team reports this week. The new study, in the journal Cerebral Cortex, found that nearly a quarter of the variability in achievement seen among men and women trained on a new video game could be predicted by measuring the volume of three structures in their brains. The study adds to the evidence that specific parts of the striatum, a collection of...

2009-08-05 08:00:00

SAN DIEGO, Aug. 5 /PRNewswire/ -- Ceregene, Inc. today announced that the Michael J. Fox Foundation will provide partial funds for long-term follow-up testing of patients enrolled in the company's Phase 2 trial of CERE-120 for Parkinson's disease. The funding will enable Ceregene to collect and analyze more extensive data for up to 48 months from patients with advanced Parkinson's disease who were enrolled in the double-blind, controlled trial which ended in November 2008. As was...

2009-05-27 06:00:00

-- Longer term follow-up indicates modest efficacy in primary and related endpoints -- SAN DIEGO, May 27 /PRNewswire/ -- Ceregene, Inc. today reported additional clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. CERE-120 uses AAV-based gene therapy to deliver the neurotrophic factor, neurturin, to Parkinson's disease patients in order to restore the function and protect degenerating nigrostriatal neurons. The...


Word of the Day
omphalos
  • The navel or umbilicus.
  • In Greek archaeology: A central boss, as on a shield, a bowl, etc.
  • A sacred stone in the temple of Apollo at Delphi, believed by the Greeks to mark the 'navel' or exact center-point of the earth.
'Omphalos' comes from the ancient Greek.
Related